Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

1st Patient Treated in Phase 3 Trial of RDEB Gene Therapy, D-Fi

A first patient has been treated in a Phase 3 trial testing the investigational gene therapy D-Fi (debcoemagene autoficel), formerly known as FCX-007, on wounds in people with recessive dystrophic epidermolysis bullosa (RDEB). "Our late-stage Phase 3 trial of D-Fi continues to progress for the...